[1] |
Costantino S, Paneni F, Cosentino F. Ageing, metabolism and cardiovascular disease. J Physiol, 2016; 594, 2061−73. doi: 10.1113/JP270538 |
[2] |
Hou YJ, Dan XL, Babbar M, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol, 2019; 15, 565−81. doi: 10.1038/s41582-019-0244-7 |
[3] |
North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res, 2012; 110, 1097−108. doi: 10.1161/CIRCRESAHA.111.246876 |
[4] |
Ungvari Z, Tarantini S, Donato AJ, et al. Mechanisms of vascular aging. Circ Res, 2018; 123, 849−67. doi: 10.1161/CIRCRESAHA.118.311378 |
[5] |
Seals DR, Alexander LM. Vascular aging. J Appl Physiol (1985), 2018; 125, 1841−2. doi: 10.1152/japplphysiol.00448.2018 |
[6] |
Thijssen DHJ, Carter SE, Green DJ. Arterial structure and function in vascular ageing: are you as old as your arteries?. J Physiol, 2016; 594, 2275−84. doi: 10.1113/JP270597 |
[7] |
Cao QD, Wu JP, Wang XL, et al. Noncoding RNAs in vascular aging. Oxid Med Cell Longev, 2020; 2020, 7914957. |
[8] |
Guzik TJ, Touyz RM. Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension, 2017; 70, 660−7. doi: 10.1161/HYPERTENSIONAHA.117.07802 |
[9] |
Wang MY, Kim SH, Monticone RE, et al. Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis. Hypertension, 2015; 65, 698−703. doi: 10.1161/HYPERTENSIONAHA.114.03618 |
[10] |
Barallobre-Barreiro J, Loeys B, Mayr M, et al. Extracellular matrix in vascular disease, part 2/4: JACC focus seminar. J Am Coll Cardiol, 2020; 75, 2189−203. |
[11] |
Cheng XW, Kuzuya M, Nakamura K, et al. Mechanisms underlying the impairment of ischemia-induced neovascularization in matrix metalloproteinase 2–deficient mice. Circ Res, 2007; 100, 904−13. doi: 10.1161/01.RES.0000260801.12916.b5 |
[12] |
Vigetti D, Moretto P, Viola M, et al. Matrix metalloproteinase 2 and tissue inhibitors of metalloproteinases regulate human aortic smooth muscle cell migration during in vitro aging. FASEB J, 2006; 20, 1118−30. doi: 10.1096/fj.05-4504com |
[13] |
Wang MY, Monticone RE, McGraw KR. Proinflammation, profibrosis, and arterial aging. Aging Med, 2020; 3, 159−68. doi: 10.1002/agm2.12099 |
[14] |
Spiers JP, Kelso EJ, Siah WF, et al. Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade. J Hypertens, 2005; 23, 1717−24. doi: 10.1097/01.hjh.0000176787.04753.ee |
[15] |
Piao LM, Zhao GX, Zhu EB, et al. Chronic psychological stress accelerates vascular senescence and impairs ischemia‐induced neovascularization: the role of dipeptidyl peptidase‐4/glucagon‐like peptide‐1‐adiponectin axis. J Am Heart Assoc, 2017; 6, e006421. doi: 10.1161/JAHA.117.006421 |
[16] |
Xu SN, Piao LM, Wan Y, et al. CTSS modulates stress-related carotid artery thrombosis in a mouse FeCl3 model. Arterioscler Thromb Vasc Biol, 2023; 43, e238−53. |
[17] |
Lei YN, Yang G, Hu LN, et al. Increased dipeptidyl peptidase-4 accelerates diet-related vascular aging and atherosclerosis in ApoE-deficient mice under chronic stress. Int J Cardiol, 2017; 243, 413−20. doi: 10.1016/j.ijcard.2017.05.062 |
[18] |
Kim S, Misra A. SNP genotyping: technologies and biomedical applications. Annu Rev Biomed Eng, 2007; 9, 289−320. doi: 10.1146/annurev.bioeng.9.060906.152037 |
[19] |
Shimizu S, Mimura J, Hasegawa T, et al. Association of single nucleotide polymorphisms in the NRF2 promoter with vascular stiffness with aging. PLoS One, 2020; 15, e0236834. doi: 10.1371/journal.pone.0236834 |
[20] |
Liao YC, Liu PY, Lin HF, et al. Two functional polymorphisms of ROCK2 enhance arterial stiffening through inhibiting its activity and expression. J Mol Cell Cardiol, 2015; 79, 180−6. doi: 10.1016/j.yjmcc.2014.11.023 |
[21] |
Vlachopoulos C, Xaplanteris P, Baou K, et al. Common single nucleotide polymorphisms of the p22phox NADPH oxidase subunit do not influence aortic stiffness in young, healthy adults. Hellenic J Cardiol, 2012; 53, 352−6. |
[22] |
Cunha PG, Boutouyrie P, Nilsson PM, et al. Early vascular ageing (EVA): definitions and clinical applicability. Curr Hypertens Rev, 2017; 13, 8−15. |
[23] |
The Reference Values for Arterial Stiffness’ Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J, 2010; 31, 2338−50. doi: 10.1093/eurheartj/ehq165 |
[24] |
He H, Deng Y, Wan H, et al. Urinary bisphenol A and its interaction with CYP17A1 rs743572 are associated with breast cancer risk. Chemosphere, 2022; 286, 131880. doi: 10.1016/j.chemosphere.2021.131880 |
[25] |
Cabral-Pacheco GA, Garza-Veloz I, Castruita-De La Rosa C, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci, 2020; 21, 9739. doi: 10.3390/ijms21249739 |
[26] |
Perrocheau M, Kiando SR, Vernerey D, et al. Investigation of the matrix metalloproteinase-2 gene in patients with non-syndromic mitral valve prolapse. J Cardiovasc Dev Dis, 2015; 2, 176−89. |
[27] |
Basalyga DM, Simionescu DT, Xiong WF, et al. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation, 2004; 110, 3480−7. doi: 10.1161/01.CIR.0000148367.08413.E9 |
[28] |
Thompson M, Cockerill G. Matrix metalloproteinase-2: the forgotten enzyme in aneurysm pathogenesis. Ann N Y Acad Sci, 2006; 1085, 170−4. doi: 10.1196/annals.1383.034 |
[29] |
Qi FR, Liu Y, Zhang KL, et al. Artificial intelligence uncovers natural MMP inhibitor crocin as a potential treatment of thoracic aortic aneurysm and dissection. Front Cardiovasc Med, 2022; 9, 871486. doi: 10.3389/fcvm.2022.871486 |
[30] |
Zehtabi F, Ispas-Szabo P, Djerir D, et al. Chitosan-doxycycline hydrogel: an MMP inhibitor/sclerosing embolizing agent as a new approach to endoleak prevention and treatment after endovascular aneurysm repair. Acta Biomater, 2017; 64, 94−105. doi: 10.1016/j.actbio.2017.09.021 |
[31] |
Kroon AM, Taanman JW. Clonal expansion of T cells in abdominal aortic aneurysm: a role for doxycycline as drug of choice? Int J Mol Sci, 2015; 16, 11178-95. |
[32] |
Elahirad S, Elieh Ali Komi D, Kiani A, et al. Association of matrix metalloproteinase-2 (MMP-2) and MMP-9 promoter polymorphisms, their serum levels, and activities with coronary artery calcification (CAC) in an Iranian population. Cardiovasc Toxicol, 2022; 22, 118−29. doi: 10.1007/s12012-021-09707-5 |
[33] |
Alg VS, Ke XY, Grieve J, et al. Association of functional MMP-2 gene variant with intracranial aneurysms: case-control genetic association study and meta-analysis. Br J Neurosurg, 2018; 32, 255−9. doi: 10.1080/02688697.2018.1427213 |
[34] |
Wu WX, Liu DY, Jiang SL, et al. Polymorphisms in gene MMP-2 modify the association of cadmium exposure with hypertension risk. Environ Int, 2019; 124, 441−7. doi: 10.1016/j.envint.2019.01.041 |
[35] |
Wang N, Zhou S, Fang XC, et al. MMP-2, -3 and TIMP-2, -3 polymorphisms in colorectal cancer in a Chinese Han population: a case-control study. Gene, 2020; 730, 144320. doi: 10.1016/j.gene.2019.144320 |
[36] |
Tsai EM, Wang YS, Lin CS, et al. A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women. J Hum Genet, 2013; 58, 202−9. doi: 10.1038/jhg.2013.1 |
[37] |
Fatar M, Stroick M, Steffens M, et al. Single-nucleotide polymorphisms of MMP-2 gene in stroke subtypes. Cerebrovasc Dis, 2008; 26, 113−9. doi: 10.1159/000139657 |
[38] |
Deshmane SL, Kremlev S, Amini S, et al. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res, 2009; 29, 313−26. doi: 10.1089/jir.2008.0027 |
[39] |
Zhu SP, Liu M, Bennett S, et al. The molecular structure and role of CCL2 (MCP‐1) and C‐C chemokine receptor CCR2 in skeletal biology and diseases. J Cell Physiol, 2021; 236, 7211−22. doi: 10.1002/jcp.30375 |
[40] |
Singh S, Anshita D, Ravichandiran V. MCP-1: function, regulation, and involvement in disease. Int Immunopharmacol, 2021; 101, 107598. doi: 10.1016/j.intimp.2021.107598 |
[41] |
Wang MY, Spinetti G, Monticone RE, et al. A local proinflammatory signalling loop facilitates adverse age-associated arterial remodeling. PLoS One, 2011; 6, e16653. doi: 10.1371/journal.pone.0016653 |
[42] |
Zhang HX, Yang K, Chen F, et al. Role of the CCL2-CCR2 axis in cardiovascular disease: pathogenesis and clinical implications. Front Immunol, 2022; 13, 975367. doi: 10.3389/fimmu.2022.975367 |
[43] |
Guo X, Cai DP, Dong K, et al. DOCK2 deficiency attenuates abdominal aortic aneurysm formation—brief report. Arterioscler Thromb Vasc Biol, 2023; 43, e210−7. |
[44] |
Brenner D, Labreuche J, Touboul PJ, et al. Cytokine polymorphisms associated with carotid intima-media thickness in stroke patients. Stroke, 2006; 37, 1691−6. doi: 10.1161/01.STR.0000226565.76113.6c |
[45] |
Jemaa R, Rojbani H, Kallel A, et al. Association between the −2518G/A polymorphism in the monocyte chemoattractant protein-1 (MCP-1) gene and myocardial infarction in Tunisian patients. Clin Chim Acta, 2008; 390, 122−5. doi: 10.1016/j.cca.2008.01.004 |
[46] |
Xu ZH, Li J, Yang HY, et al. Association of CCL2 gene variants with osteoarthritis. Arch Med Res, 2019; 50, 86−90. doi: 10.1016/j.arcmed.2019.05.014 |
[47] |
Feng WX, Mokrousov I, Wang BB, et al. Tag SNP polymorphism of CCL2 and its role in clinical tuberculosis in Han Chinese pediatric population. PLoS One, 2011; 6, e14652. doi: 10.1371/journal.pone.0014652 |
[48] |
Motsinger AA, Ritchie MD. Multifactor dimensionality reduction: an analysis strategy for modelling and detecting gene - gene interactions in human genetics and pharmacogenomics studies. Hum Genomics, 2006; 2, 318. doi: 10.1186/1479-7364-2-5-318 |